Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Purchases 66,057 Shares

Immunome, Inc. (NASDAQ:IMNMGet Free Report) CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction on Thursday, November 21st. The shares were acquired at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the completion of the transaction, the chief executive officer now owns 485,693 shares of the company’s stock, valued at $4,633,511.22. This represents a 15.74 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Immunome Price Performance

Shares of IMNM stock opened at $11.15 on Tuesday. The company’s fifty day moving average price is $12.49 and its two-hundred day moving average price is $13.55. The firm has a market capitalization of $695.98 million, a P/E ratio of -1.37 and a beta of 1.82. Immunome, Inc. has a 12 month low of $6.93 and a 12 month high of $30.96.

Analysts Set New Price Targets

A number of analysts recently weighed in on IMNM shares. Stephens assumed coverage on shares of Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target for the company. Piper Sandler decreased their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Friday, October 25th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $28.83.

Check Out Our Latest Stock Report on Immunome

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Arizona State Retirement System grew its stake in Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares in the last quarter. Clear Creek Financial Management LLC boosted its stake in shares of Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after buying an additional 4,035 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after buying an additional 4,129 shares in the last quarter. Cerity Partners LLC increased its stake in shares of Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after buying an additional 5,043 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Immunome in the second quarter valued at $81,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

(Get Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Recommended Stories

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.